. 2014 May 25;2014:185716. doi: 10.1155/2014/185716

Table 2.

Antioxidants status in the tissue and blood of mice in each group.

Index	Group^C	Brain	Liver	Kidney	Serum
MDA (nmol/mg prot or nmol/mL)	Model	7.09 ± 1.27	4.31 ± 1.10	5.07 ± 0.71	7.07 ± 0.58
	Control	5.47 ± 0.62^a	2.23 ± 0.97^a	3.89 ± 0.51^a	5.21 ± 0.58^a
	VC	4.87 ± 0.94^b	2.27 ± 0.36^b	3.80 ± 0.68^a	4.92 ± 0.22^a
	Low dose	5.53 ± 0.39^a	3.21 ± 1.15	4.76 ± 0.77	5.11 ± 0.70^a
	Medium dose	4.77 ± 0.51^b#	2.57 ± 0.48^a	3.61 ± 0.80^b	4.73 ± 0.20^a
	High dose	4.16 ± 0.50^b##	2.03 ± 0.63^b	2.87 ± 0.53^bA#	5.44 ± 0.63^a

SOD (U/mg prot or U/mL)	Model	139.29 ± 17.74	281.25 ± 31.04	153.42 ± 5.21	96.64 ± 4.39
	Control	211.64 ± 38.02^b	368.10 ± 35.78^b	195.91 ± 16.30^b	121.70 ± 9.45^a
	VC	181.12 ± 29.52^b	384.02 ± 27.66^b	145.91 ± 16.87^##	131.65 ± 13.05^a
	Low dose	158.62 ± 21.84^a#	349.21 ± 34.90^aA	171.10 ± 14.59^aA#	96.41 ± 10.65^A
	Medium dose	167.80 ± 33.06^a#	353.29 ± 22.14^bA	184.68 ± 13.35^bB	102.26 ± 5.46^A#
	High dose	175.24 ± 22.22^b#	320.61 ± 35.27^aB#	189.27 ± 14.75^bB	115.62 ± 8.24^a

GSH (mgGSH/g prot or mgGSH/L)	Model	2.96 ± 0.70	1.10 ± 0.20	1.52 ± 0.25	6.81 ± 0.58
	Control	5.59 ± 0.86^b	1.72 ± 0.10^b	2.53 ± 0.16^b	12.56 ± 0.40^b
	VC	3.93 ± 0.45^a##	1.59 ± 0.19^a	2.29 ± 0.26^b	7.68 ± 0.38^##
	Low dose	4.52 ± 0.86^a#	1.30 ± 0.33^#	1.63 ± 0.35^B##	7.62 ± 0.34^##
	Medium dose	5.83 ± 0.66^bB	1.56 ± 0.35^b	1.99 ± 0.29^b#	7.98 ± 0.21^a##
	High dose	7.09 ± 0.98^bB#	2.32 ± 0.33^bB##	2.52 ± 0.33^b	9.17 ± 0.42^bA##

GSH-Px (U/mg prot or U/mL)	Model	×	415.35 ± 47.62	114.84 ± 8.83	459.67 ± 27.24
	Control		657.42 ± 53.53^b	174.17 ± 11.01^b	680.33 ± 21.51^b
	VC		511.67 ± 23.93^b##	159.10 ± 16.63^b	626.41 ± 16.88^b#
	Low dose		430.81 ± 42.50^B##	151.54 ± 21.95^b#	508.21 ± 20.52^aB##
	Medium dose		602.80 ± 67.82^bB#	169.50 ± 16.33^b	650.73 ± 14.10^bA
	High dose		493.69 ± 34.11^b##	194.91 ± 20.63^bB#	576.38 ± 14.50^bA##

CAT (U/g prot or U/mL)	Model	×	295.67 ± 36.16	120.01 ± 13.85	5.42 ± 0.29
	Control		340.24 ± 34.51^a	166.53 ± 34.24^b	9.71 ± 0.70^b
	VC		394.63 ± 62.56^b	149.67 ± 29.17^a	12.91 ± 1.19^b
	Low dose		317.88 ± 22.79^A	148.28 ± 24.34^a	8.61 ± 0.47^bB
	Medium dose		403.77 ± 41.93^b#	233.29 ± 42.72^bB#	9.67 ± 0.20^bA
	High dose		522.61 ± 31.60^bB##	158.70 ± 24.30^a	11.42 ± 0.27^b#

T-AOC (U/mg prot or U/mL)	Model	0.83 ± 0.21	1.23 ± 0.10	0.59 ± 0.06	4.56 ± 0.39
	Control	1.41 ± 0.28^b	1.66 ± 0.17^b	1.00 ± 0.15^b	6.52 ± 0.28^b
	VC	2.48 ± 0.23^b##	1.36 ± 0.22^#	0.46 ± 0.08^##	6.78 ± 0.04^b
	Low dose	1.38 ± 0.22^bB	1.34 ± 0.10^#	1.18 ± 0.08^bB#	5.38 ± 0.23^aA#
	Medium dose	1.53 ± 0.24^bB	1.58 ± 0.16^b	1.25 ± 0.11^bB#	5.85 ± 0.26^bA#
	High dose	1.92 ± 0.15^bB##	1.88 ± 0.16^bB#	1.48 ± 0.13^bB##	6.31 ± 0.30^b

Values are the mean ± SD.

× means undetected.

^a P < 0.05; ^b P < 0.01 compared with model group (all groups). ^A P < 0.05; ^B P < 0.01 compared with VC group (EAE groups). ^# P < 0.05; ^## P < 0.01 compared with control group (VC and EAE groups). ^CVC group (100 mg/kg); low dose EAE group (100 mg/kg); medium dose EAE group (200 mg/kg); high dose EAE group (400 mg/kg).